Lab1636

Lab1636 is a translational research company established through a strategic collaboration between Harvard University and Deerfield Management. Launched in 2019 with a $100 million funding commitment from Deerfield, the company is designed to accelerate the development of basic science discoveries from Harvard's laboratories into novel therapeutics. Lab1636 provides the financial and operational resources necessary to advance promising academic projects through the early stages of drug discovery and preclinical development. The partnership focuses on a broad range of therapeutic areas and modalities, leveraging Harvard's research excellence and Deerfield's expertise in drug development and commercialization.